Use of High-Dose, Twice-Yearly Albendazole and Ivermectin to Suppress *Wuchereria bancrofti* Microfilarial Levels

Benoit Dembele,1 Yaya I. Coulibaly,1 Housseini Dolo,1 Siaka Konate,1 Siaka Y. Coulibaly,1 Dramane Sanogo,1 Lamine Soumaoro,1 Michel E. Coulibaly,1 Salif Seriba Doumbia,1 Abdallah A. Diallo,1 Sekou F. Traore,1 Adama Diaman Keita,2 Michael P. Fay,3 Thomas B. Nutman,4 and Amy D. Klion4

1Faculty of Medicine, Pharmacy and Dentistry, Filariasis Unit, University of Bamako, and 2Department of Radiology, Hospital of Point G, Bamako, Mali; and 3Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, and 4Laboratory of Parasitic Diseases, National Institutes of Health, Bethesda, Maryland

(See the editorial commentary by Kazura, on pages 1236–1237.)

**Background.** Annual mass treatment with albendazole and ivermectin is the mainstay of current strategies to interrupt transmission of *Wuchereria bancrofti* in Africa. More-effective microfilarial suppression could potentially reduce the time necessary to interrupt transmission, easing the economic burden of mass treatment programs in countries with limited resources.

**Methods.** To determine the effect of increased dose and frequency of albendazole-ivermectin treatment on microfilarial clearance, 51 *W. bancrofti* microfilaremic residents of an area of *W. bancrofti* endemicity in Mali were randomized to receive 2 doses of annual, standard-dose albendazole-ivermectin therapy (400 mg and 150 μg/kg; *n* = 26) or 4 doses of twice-yearly, increased-dose albendazole-ivermectin therapy (800 mg and 400 μg/kg; *n* = 25).

**Results.** Although microfilarial levels decreased significantly after therapy in both groups, levels were significantly lower in the high-dose, twice-yearly group at 12, 18, and 24 months. Furthermore, there was complete clearance of detectable microfilariae at 12 months in the 19 patients in the twice-yearly therapy group with data available at 12 months, compared with 9 of 21 patients in the annual therapy group (*P* < .001, by Fisher’s exact test). This difference between the 2 groups was sustained at 18 and 24 months, with no detectable microfilariae in the patients receiving twice-yearly treatment. Worm nests detectable by ultrasonography and *W. bancrofti* circulating antigen levels, as measured by enzyme-linked immunosorbent assay, were decreased to the same degree in both groups at 24 months, compared with baseline.

**Conclusions.** These findings suggest that increasing the dosage and frequency of albendazole-ivermectin treatment enhances suppression of microfilariae but that this effect may not be attributable to improved adulticidal activity.

More than 120 million people in approximately 80 countries are infected with the mosquito-transmitted filarial nematodes, *Wuchereria bancrofti* or *Brugia* species. Furthermore, it is estimated that >40 million people have chronic, disabling disease manifestations, including lymphedema, hydrocele, and elephantiasis. Despite successful elimination programs in some countries [1], transmission of lymphatic filariasis remains a problem in many regions of the world. This is particularly true in resource-poor areas of Africa, including Mali, where sustaining the World Health Organization–approved mass treatment regimen of single-dose albendazole (400 mg) and ivermectin (150–200 μg/kg) annually for 4–6 years poses a significant financial burden [2]. Because microfilarial levels in the blood are directly responsible for continued transmission by the mosquito vectors, a more effective suppressive regimen could accelerate the interruption of transmission and
shorten the overall duration of the mass treatment program.

Currently available antifilarial drugs with activity against *W. bancrofti*, the agent of lymphatic filariasis in Africa, include ivermectin, diethylcarbamazine, albendazole, and doxycycline. Of these, ivermectin and diethylcarbamazine have each been shown to be effective in clearing microfilariae from the circulation after single-dose therapy [3], although diethylcarbamazine is contraindicated in most of Africa because of the risk of severe (and possibly life-threatening) posttreatment reactions in patients with concomitant onchocerciasis. The demonstration that the addition of albendazole (400 mg) to annual, single-dose therapy with ivermectin (200 µg/kg) prolonged the suppression of microfilaremia without any noticeable increase in adverse effects or posttreatment reactions provided the basis for the current World Health Organization recommendation of annual single-dose ivermectin-albendazole for lymphatic filariasis elimination in Africa [4].

Although early studies in French Polynesia suggested that increased dosage (400 µg/kg) or twice-yearly administration of ivermectin alone was more effective than standard annual therapy in reducing *W. bancrofti* microfilaremia [5, 6], the effects of these parameters in the setting of combination therapy are unknown. The current study was designed to assess whether twice-yearly administration of albendazole-ivermectin at an increased dosage (800 mg and 400 µg/kg, respectively) is more effective in suppressing microfilarial levels than the current World Health Organization–approved regimen. The effects of this regimen on adult worm burden, as assessed by serum levels of circulating filarial antigen and ultrasonography, were also explored.

**STUDY POPULATION AND METHODS**

**Study population.** The study was conducted in the villages of Tienekebougou and Bougoudiana, ~105 km northwest of Bamako, Mali. Prior studies in these villages had demonstrated
a high prevalence of *W. bancrofti* microfilaremia. This region is outside the area of endemicity for onchocerciasis. Patients had received a single dose of albendazole and ivermectin as part of the National Program to Eliminate Lymphatic Filariasis 1 year before the start of the study. The study (NCT00339417) was approved by the ethical review committees of the Faculty of Medicine, Pharmacy, and Dentistry at the University of Bamako (Bamako, Mali) and of the National Institutes of Allergy and Infectious Diseases (Bethesda, Maryland). Community permission for the study was obtained from village elders, and individual oral or written informed consent was obtained from all participants in French or Bambara, the local language.

Nonpregnant volunteers (n = 390) of both sexes, 14–65 years of age, were screened with a brief medical history and physical examination and venipuncture between 10 pm and 2 am for detection of *W. bancrofti* microfilaremia by calibrated thick smear of 60 μL of blood, assessment of *W. bancrofti* circulating antigen levels by enzyme-linked immunosorbent assay (TropBio), and hemoglobin level (Figure 1). Patients were excluded from participating in the drug study for the following reasons: a *W. bancrofti* microfilarial level of <50 microfilariae/mL; pregnancy, hemoglobin level <9 g/dL, heavy alcohol use (>7 beers or other alcohol-containing drinks per week), temperature >37.5°C, serious medical illness, history of allergy to benzimidazoles or ivermectin, or use of albendazole or ivermectin within the past 6 months.

**Study design.** Eligible participants were randomly assigned to receive annual treatment with standard-dose albendazole (400 mg) and ivermectin (150 μg/kg) or twice-yearly treatment with high-dose albendazole (800 mg) and ivermectin (400 μg/kg) for 24 months (Figure 1). A brief clinical assessment, including vital signs and pregnancy testing (in women of child-bearing age), was performed at each study time point. Study medication was administered under the direct observation of a physician who remained in the study village for 1 week after treatment to assess adverse events. Venipuncture was performed between 10 pm and 2 am at baseline and every 6 months before treatment for quantification of *W. bancrofti* microfilarial levels (by Nuclepore filtration of 1 mL of blood) and circulating antigen levels, as well as complete blood cell count. All laboratory assessments were performed by trained personnel unaware of the group assignments. Ultrasonography was performed for male and female volunteers at baseline to identify adult worms in the scrotal and breast lymphatics (filarial dance sign) [7]. Additional ultrasonography was performed at 12 and 24 months. An experienced radiologist, blinded to the study group assignments, performed all ultrasound studies.

**Statistical analysis.** The primary end point of the study was the difference in *W. bancrofti* levels between the 2 groups at 12 months. This was evaluated by examining the *W. bancrofti* clearance rates at 12 months using 2-sided Fisher’s exact test and matching confidence intervals [8] and by assessing the difference in the percentage of baseline *W. bancrofti* microfilarial levels at 12 months by Wilcoxon-Mann-Whitney U test. The Fisher’s exact test was performed for all patients with complete data at 12, 18, and 24 months and, in addition, for all randomized patients at 12 months using a conservative pooled imputation sensitivity analysis, where the missing patients in each group are imputed with proportions closest to the total proportion of responders, regardless of treatment group [9]. On the basis of the published data comparing single and multidose regimens for the treatment of lymphatic filariasis [10] and a predicted 10% attrition rate, a sample size of 25 per group was estimated to have 90% power to detect a difference in the 2 groups by Fisher’s exact test with a 2-sided α level of .05. One patient in the annual group and 2 patients in the twice-yearly group had no detectable *W. bancrofti* microfilariae at the baseline visit despite a microfilarial level of >50 micro-

### Table 1. Baseline Characteristics of the Study Population

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Annual standard dose (n = 22)</th>
<th>Twice-yearly high dose (n = 20)</th>
<th>p*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, median (range), years</td>
<td>45 (18–62)</td>
<td>53 (21–59)</td>
<td>.50</td>
</tr>
<tr>
<td>Male/female</td>
<td>15/7</td>
<td>15/5</td>
<td>.74c</td>
</tr>
<tr>
<td><em>Wuchereria bancrofti</em> microfilarial level, median (range), microfilariae/mL</td>
<td>161 (0–1530)</td>
<td>195 (0–1850)</td>
<td>.62</td>
</tr>
<tr>
<td><em>Mansonella perstans</em> microfilarial level, median (range), microfilariae/mL</td>
<td>47 (0–958)</td>
<td>98 (0–558)</td>
<td>.92</td>
</tr>
<tr>
<td>Eosinophil count, geometric mean (range), cells/mm³</td>
<td>606 (224–1995)</td>
<td>566 (92–3484)</td>
<td>.44</td>
</tr>
<tr>
<td><em>W. bancrofti</em> circulating antigen level, geometric mean (range), U/mL</td>
<td>7508 (302–140,421)</td>
<td>5632 (641–38,079)</td>
<td>.93</td>
</tr>
<tr>
<td>Proportion (%) of patients with worm nest detected</td>
<td>9/21 (43)</td>
<td>7/19 (37)</td>
<td>.76c</td>
</tr>
</tbody>
</table>

**NOTE.** Data given are from the baseline visit immediately before treatment, at which time 2 patients in the annual group and 1 patient in the twice-yearly group had no detectable microfilarial levels. Per the study inclusion criteria, all enrolled patients had *W. bancrofti* microfilarial levels of >50 microfilariae/mL detected at the screening visit.

* a Mann-Whitney U test, unless otherwise indicated.
* b Fisher’s exact test.
* c No. of men in whom at least 1 worm nest was detected by ultrasonography/total no. of patients who underwent ultrasonography. No worm nests were detected in women in either group.
Table 2. Adverse Events in the 2 Study Groups

<table>
<thead>
<tr>
<th>Adverse event, patient</th>
<th>Treatment group</th>
<th>Study point</th>
<th>Grade</th>
<th>Duration, days</th>
<th>Relatedness to study drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urticaria, Tie012</td>
<td>Annual</td>
<td>Baseline</td>
<td>2</td>
<td>1</td>
<td>D</td>
</tr>
<tr>
<td>Epigastric pain, Tie187</td>
<td>Twice yearly</td>
<td>Baseline</td>
<td>2</td>
<td>4</td>
<td>P</td>
</tr>
<tr>
<td>Angioedema</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tie022</td>
<td>Annual</td>
<td>Baseline</td>
<td>1</td>
<td>1</td>
<td>D</td>
</tr>
<tr>
<td>Tie132</td>
<td>Annual</td>
<td>Baseline</td>
<td>2</td>
<td>3</td>
<td>D</td>
</tr>
<tr>
<td>Tie145</td>
<td>Twice yearly</td>
<td>Month 12</td>
<td>1</td>
<td>2</td>
<td>D</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bou138</td>
<td>Annual</td>
<td>Month 6</td>
<td>1</td>
<td>NA&lt;sup&gt;b&lt;/sup&gt;</td>
<td>N</td>
</tr>
<tr>
<td>Bou156</td>
<td>Annual</td>
<td>Month 12</td>
<td>1</td>
<td>8</td>
<td>N</td>
</tr>
<tr>
<td>Tie008</td>
<td>Twice yearly</td>
<td>Month 6</td>
<td>1</td>
<td>2</td>
<td>P</td>
</tr>
<tr>
<td>Diarrhea</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bou138</td>
<td>Annual</td>
<td>Month 6</td>
<td>1</td>
<td>NA&lt;sup&gt;c&lt;/sup&gt;</td>
<td>N</td>
</tr>
<tr>
<td>Bou140</td>
<td>Twice yearly</td>
<td>Month 6</td>
<td>1</td>
<td>2</td>
<td>P</td>
</tr>
<tr>
<td>Aphthous ulcer, Bou156</td>
<td>Annual</td>
<td>Month 24</td>
<td>1</td>
<td>4</td>
<td>N</td>
</tr>
<tr>
<td>Incarcerated hernia, Tie008</td>
<td>Twice yearly</td>
<td>Month 6</td>
<td>3</td>
<td>5</td>
<td>N</td>
</tr>
</tbody>
</table>

**NOTE.** Adverse events occurring at the study time point and for up to 7 days thereafter are reported. D, definitely related; N, not related. NA<sup>b</sup>, not available; P, possibly related.

<sup>a</sup> 1, Mild; 2, moderate; 3, severe; and 4, life-threatening or disabling.

<sup>b</sup> As assessed by the study physician.

<sup>c</sup> Abdominal pain and diarrhea were reported at the 6-month time point in a patient who did not return to report resolution of symptoms. This patient was in the annual group and had not received albendazole-ivermectin treatment at this point. The symptoms resolved by the time of the 12-month follow-up.

RESULTS

Study population. Patients were recruited and screened in April 2007 and began treatment in July 2007. On the basis of the screening results, 51 eligible patients were identified and randomized to receive standard, annual therapy (n = 26) or high-dose, twice-yearly therapy (n = 25). Seven patients (3 in the annual group and 4 in the twice-yearly group) declined to participate before enrollment, and 2 (1 in each group) signed consent but refused to undergo venipuncture at the baseline visit, leaving 42 patients (22 in the annual group and 20 in the twice-yearly group) in the treatment portion of the study. There were no significant differences between the 2 groups at baseline with respect to median age, sex distribution, eosinophil count, W. bancrofti microfilarial or circulating antigen levels, or the prevalence of worm nests detected by ultrasonography (Table 1). Clinical disease associated with lymphatic filariasis was uncommon in both groups, with hydrocele found in only 3 patients (2 in the annual group and 1 in the twice-yearly group) and a history of lymphedema in only 1 subject (in the annual group). Sixteen patients (8 in each group) reported a history of lymphangitis occurring >1 month before the study. As has been reported in previous studies in this region of Mali, most W. bancrofti–infected patients (38 [90%] of 42) were coinfected with Mansonella perstans.

Adverse events. A total of 12 adverse events were reported by 9 study patients (17%). Mild-to-moderate adverse events were reported in both treatment groups and included gastrointestinal symptoms, urticaria, and localized angioedema, all of which are consistent with known effects of anthelmintic (albendazole-ivermectin) therapy (Table 2). None of the patients with angioedema demonstrated respiratory or laryngeal symptoms. The only serious adverse event, an incarcerated hernia requiring surgical intervention, was categorized as unrelated to the study procedures.

Efficacy. As expected, microfilarial levels decreased significantly in both groups after albendazole-ivermectin treatment (Figure 2). Nevertheless, the percentages of pretreatment W. bancrofti microfilarial levels were significantly decreased in the high-dose, semiannual group at 12, 18, and 24 months com-
High-Dose Treatment for Filariasis

Figure 2. Reduction of microfilaremia after high-dose, twice-yearly albendazole and ivermectin (A), compared with standard-dose annual treatment (B). Each symbol represents the value for an individual patient. The horizontal line indicates the geometric mean for the group. *P < .05, annual versus twice-yearly treatment (Wilcoxon-Mann-Whitney U test).

Figure 3. Clearance of microfilaremia after high-dose, twice-yearly albendazole and ivermectin, compared with standard-dose annual treatment. The bars represent the percentage of patients with detectable Wuchereria bancrofti microfilariae at baseline and 6, 12, 18, and 24 months after treatment. Annual, standard-dose treatment is indicated by the black bars and high-dose, twice-yearly treatment is indicated by the white bars. *P < .05, annual versus twice-yearly treatment (Fisher’s exact test).

DISCUSSION

Although mass treatment with albendazole and ivermectin has proven to be a successful strategy for the suppression of W. bancrofti microfilarial counts in a variety of settings, elimination of transmission has been reported exclusively in countries where diethylcarbamazine has been administered for many
years [11–13]. Early estimates of the length of time required to eliminate transmission of *W. bancrofti* infection were based on the assumption that single-dose antifilarial therapy administered annually for the 4- to 6-year mean reproductive life span of the parasite would be sufficient to permanently interrupt transmission [14]. More recently, computer simulations have demonstrated that the number of years needed to eliminate transmission depends not only on the life span of the parasite but also on the vector species, treatment coverage, drug efficacy, and baseline endemicity [15, 16]. The influence of at least 1 of these parameters, baseline endemicity, on the reduction of transmission has been validated in the field [17]. Drug efficacy is likely to play at least as important a role.

Although a number of studies have suggested that diethylcarbamazine-containing regimens are more effective than ivermectin and albendazole, the use of diethylcarbamazine to enhance efficacy of mass treatment is contraindicated in most of Africa, including Mali, because of the presence of onchocerciasis. Thus, other methods of enhancing drug efficacy are required in these regions. In the present study, we examined the effects of increased dose and duration of albendazole and ivermectin treatment on the suppression of microfilaremia in an area of lymphatic filariasis endemicity in Mali. Not only did the higher, more frequent dosing lead to reduced levels of microfilaremia at 12, 18, and 24 months, but also microfilariae were undetectable in the peripheral blood specimens of all patients in the high-dose, twice-yearly group at these time points. At the community level, enhanced clearance of blood microfilariae could accelerate the interruption of transmission and potentially shorten the duration of mass treatment. Interestingly, no differences in circulating antigen levels or the number of worm nests were seen between the 2 groups, suggesting that the increased efficacy was not due to killing of adult worms.

Ivermectin and albendazole are broad-spectrum anthelminthics that have been shown to decrease the prevalence and intensity of intestinal helminth infections in the setting of mass distribution programs for lymphatic filariasis, providing additional benefit to treated communities [18]. In contrast, the effect of standard-dose annual ivermectin and albendazole on *M. perstans* infection has been unimpressive [19]. In the present study, median *M. perstans* microfilarial levels were unchanged from baseline in the standard annual dose group but decreased significantly in the high-dose, twice-yearly group at 12 and 18 months (Figure 5). Both groups demonstrated a significant decrease in median *M. perstans* microfilarial levels at 24 months, although the change was less remarkable in the standard-dose annual therapy group. Clearance of *M. perstans* microfilariae was observed at 24 months in only 1 of 16 *M. perstans*-positive patients in the standard-dose annual therapy group, compared with 4 of 17 in the high-dose, twice-yearly therapy group (*P* values were nonsignificant by Fisher’s exact test).

The major limitation of the present study was the lack of sufficient patients to enroll in the study groups receiving increased-dose annual treatment or standard-dose, twice-yearly treatment, precluding independent analysis of the effects of dosage and frequency of dosing on reduction of microfilaremia. This distinction is particularly important from an economic standpoint, because albendazole and ivermectin are donated by Merck and GlaxoSmithKline, respectively, whereas the cost of drug distribution is borne by the lymphatic filariasis elimination programs themselves. Although the similarity between the microfilarial levels in the standard-dose annual therapy group and

![Figure 4](https://academic.oup.com/cid/article-abstract/51/11/1229/372186/1234-CID-201051-1-December-Dembele-et-al)

**Figure 4.** Reduction of circulating antigen levels (CAg) after high-dose, twice-yearly albendazole and ivermectin (A), compared with standard-dose, annual treatment (B). Each solid line represents the percentage of pretreatment microfilarial level for an individual patient over time. The dashed line indicates the 100% pretreatment level. *P* < .05, annual versus twice-yearly treatment (Wilcoxon-Mann-Whitney U test). BL, baseline.

![Figure 5](https://academic.oup.com/cid/article-abstract/51/11/1229/372186/1234-CID-201051-1-December-Dembele-et-al)

**Figure 5.** Reduction of *Mansonella perstans* microfilarial levels after high-dose, twice-yearly albendazole and ivermectin (A), compared with standard-dose, annual treatment (B). Each solid line represents the percentage of pretreatment microfilarial level for an individual patient over time. The dashed line indicates the 100% pretreatment level. *P* < .05 compared with baseline (Wilcoxon-Mann-Whitney U test).
the high-dose, twice-yearly therapy group at 6 months suggests that frequency of treatment may be the more important factor, additional studies are needed to resolve this question.

In summary, increased-dose, twice-yearly therapy with albendazole and ivermectin was more effective in reducing *W. bancrofti* microfilarial levels than was standard-dose annual therapy in a region of high endemicity in Mali, West Africa, suggesting that more frequent and/or higher-dose therapy might accelerate the interruption of transmission. Such a strategy could be particularly useful in regions where implementation of the control program has been delayed by economic or political factors. Additional studies are clearly necessary to confirm the findings in areas of differing endemicity and to determine the relative contributions of increased dosage and increased frequency to the observed effect.

**Acknowledgments**

We thank the Mectizan Donation Program, for providing the albendazole and ivermectin used in the study, and Dr. Massitan, manager of the Malian National Program for the Elimination of Lymphatic Filariasis, and the local health care staff of Kolokani, for their cooperation and facilitation of the field studies.

**Financial support.** Intramural Research Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases, and the Task Force for Global Health (to A.D.K.).

**Potential conflicts of interest.** All authors: no conflicts.

**References**